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ABSTRACT
Creams are heterogenous biphasic semi-solid preparations consisting of oil and aqueous phases,
wherein one phase is dispersed in the other and stabilized using a suitable emulsifier. The active
pharmaceutical ingredient is either dissolved or dispersed in continuous or dispersed phase of the
formulation. Water is the most common and the major constituent in the preparation of creams.
However, certain moisture sensitive drugs like mechlorethamine, acyclovir, itraconazole and
ketoconazole are liable to degradation in presence of water thereby decreasing the stability of the
formulation. Hence, there is a need for formulation suitable for incorporating water sensitive drugs.
Creams prepared with polyethylene glycol instead of water could be an alternative to creams
prepared using water to improve the stability of the drug. Moreover, PEGs are generally used as
drug penetration enhancers and solubilizers in cream preparations. The objective of present study
was to develop and optimize Oil in PEG creams suitable for incorporating moisture sensitive drugs
and to investigate the feasibility of twin-screw processor in the continuous manufacturing of
topical semi-solid cream formulation.
Voriconazole (VRC) was selected as a model drug for preparation of Oil/PEG cream consisting of
PEG 2000, PEG 400 and propylene glycol after performing drug-excipient compatibility studies.
Twin screw processor with a 10 mm co-rotating twin screw configuration was used for preparation
of oil/PEG creams. Creams prepared using twin-screw processor were characterized for the
following: Differential Scanning Calorimetry (DSC), pH, Solvent activity (as)), viscosity, drug
content uniformity, in vitro drug release testing (IVRT) and in vitro permeation testing (IVPT)
using human cadaver skin.
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CHAPTER I: INTRODUCTION
Creams are heterogenous semi-solid preparations, where oil in water (O/W) or water in oil (W/O)
is dispersed and stabilized using a suitable emulsifier. O/W creams are most commonly used
topical formulation for various dermatological disorders. Moisture sensitive drugs like
mechlorethamine, acyclovir, itraconazole and ketoconazole are liable to degradation in water
phase. Hence, there is a need for developing cream formulation using non-aqueous hydrophilic
component. Polyethylene glycol (PEG) is a polyether compound which is produced by the
interaction of ethylene oxide with ethylene glycols and water. PEG has many applications, from
industrial manufacturing to medicine. PEG is also used as an excipient in many pharmaceutical
products. PEG is a product of condensed ethylene oxide and hydrophilic in nature. Moreover,
PEGs are generally used as drug penetration enhancers and solubilizers in cream preparation. In
the current study, PEG was used in preparation of creams instead of water, in order to overcome
the degradation of moisture sensitive drugs [1][2].
Advantages of preparation of creams using twin-screw processor over homogenization
Creams are prepared by homogenization of the ingredients which involves applying sufficient
energy to disperse one phase into another [1]. However, homogenization method for preparation of
creams has several disadvantages; 1. Homogenization is a multistep process, hence time and
resources invested in each batch is more resulting in lesser productivity and efficiency, 2.
Homogenization is a batch process; hence variations are observed between batch to batch process.
In this project, we investigated the application of hot melt extrusion (HME) technology in
1

preparation of topical semi-solid creams for continuous manufacturing of a topical semi-solid
cream formulation. HME provides many advantages over conventional method like
homogenization technique for preparation of creams, such as reduced processing time as it is
continuous process or one-step process. Moreover, the variations involved in preparation of creams
using twin screw extruder are less compared to homogenization technique. Moreover, no
additional agitators and scrapers are required since mixing action is performed by the screw
elements in the barrel. The screw elements also aid in particle size reduction. Additionally, the
processing parameters could be customized to obtain products with desired characteristics [3] with
the high yield and minimum material loss.
Active Pharmaceutical Ingredient
In this project, voriconazole (Fig. 1) an antifungal drug was selected for the study. Voriconazole
has a tendency to undergo neutral hydrolytic conditions, hence this project was designed to
incorporate voriconazole in oil/PEG creams

[31][38][39]

. Voriconazole is a triazole antifungal

medication used to treat serious fungal infections. It is used to treat invasive fungal infections that
are generally seen in patients who are immunocompromised. These include invasive candidiasis,
invasive

aspergillosis,

and

emerging

fungal

infections

caused

by Scedosporium

apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium
solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in
having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane
sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control
of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane
by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane
permeability changes and inhibition of growth.
2

Figure 1. Structure of voriconazole
Mechanism of action: Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a
depletion of ergosterol in fungal cell membrane.

Physicochemical properties of voriconazole:
The melting point of voriconazole was found to be 127-130 ºC, log P value was 1, and voriconazole
do not show any degradation at dry heat 70 ºC
propylene glycol.
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[37]

. Voriconazole is soluble in solvents like

CHAPTER II: MATERIALS AND METHODS
Materials
PEG 4500 and light mineral oil were purchased from PCCA (Houston, TX), PEG 2000 was
purchased from Sigma-Aldrich, now Millipore Sigma (Darmstadt, Germany), PEG 400 was
purchased from BASF (New Jersey, USA), Labrafil M1944 CS, Tefose 63 and Transcutol P were
kindly gifted by Gattefosse (Saint Priest, France), Menthol and Camphor were purchased from
Ward’s Science (Rochester, New York, USA) and Voriconazole (Batch no. RVK6H-QO) was
purchased from VWR (New Jersey, USA), All other chemicals and solvents (Methanol and
Acetonitrile) used were of HPLC grade. DI water was used in all studies and obtained from a
MilliQ water filtration unit.
Methods
Screening of the Excipients
Before formulation development, it is important to screen the excipients in order to develop a
stable formulation. Initial strategy included screening of the excipients for the base formulation.
Screening of the excipients was done by FTIR studies to identify any chemical interactions.
Fourier Transform Infrared Spectroscopy (FT-IR)
Understanding of physicochemical interactions of an active pharmaceutical ingredient (API) and
pharmaceutically inactive ingredients (excipients) in the dosage forms is an integral part of preformulation studies, to develop a new dosage form. Although excipients are pharmacologically

4

inert, they can interact with drugs in the dosage form to affect drug product stability, hence drug
excipient compatibility studies were performed to study the interactions [5]. Voriconazole and
excipients were analyzed using Cary 600 series Fourier transform infrared spectrometer, Agilent
Technologies (FT-IR).
Preparation and optimization of Oil/PEG cream
Oil/PEG creams were prepared by varying different grades of PEGs in combination with propylene
glycol as aqueous phase. The Oil/PEG creams F1 through F32 (table 1) was prepared by keeping
a constant amount of Voriconazole, propylene glycol, Labrafil M 1944 CS, light mineral oil, and
Tefose 63; and by varying the amount of high molecular weight/solid PEGs (PEG 4500, PEG
3350, PEG 2000, and PEG 1450 and low molecular weight/liquid PEG (PEG 400). The Oil/PEG
creams were prepared by adding the oil phase containing Tefose 63 (emulsifier) to the hydrophilic
phase at 70 °C by employing high shear homogenization technique. Labrafil M 1944 CS was used
in the oil phase because it is an excellent water dispersible surfactant, solubilizer and
bioavailability enhancer. Labrafil M 1944 CS is often used as co-emulsifier in topical formulations
along with Tefose 63 in antifungal creams [32]. The prepared creams were subjected to freeze thaw
stability studies, where the creams were exposed to 3 cycles of freeze and thaw and evaluated
visually for the phase separation of the formulation. Creams which did not undergo phase
separation were selected for the further studies.

5

Table 1. Composition of formulations used to screen Oil/PEG creams
Formulation
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14
F15
F16
F17
F18
F19
F20
F21
F22
F23
F24
F25
F26
F27
F28
F29
F30
F31
F32

Proportion of PEGs
PEG 1450: PEG 400 (15:85)
PEG 1450: PEG 400 (15:85)
PEG 1450: PEG 400 (20:80)
PEG 1450: PEG 400 (20:80)
PEG 1450: PEG 400 (30:70)
PEG 1450: PEG 400 (30:70)
PEG 1450: PEG 400 (50:50)
PEG 1450: PEG 400 (50:50)
PEG 2000: PEG 400 (15:85)
PEG 2000: PEG 400 (15:85)
PEG 2000: PEG 400 (20:80)
PEG 2000: PEG 400 (20:80)
PEG 2000: PEG 400 (30:70)
PEG 2000: PEG 400 (30:70)
PEG 2000: PEG 400 (50:50)
PEG 2000: PEG 400 (50:50)
PEG 3350: PEG 400 (15:85)
PEG 3350: PEG 400 (15:85)
PEG 3350: PEG 400 (20:80)
PEG 3350: PEG 400 (20:80)
PEG 3350: PEG 400 (30:70)
PEG 3350: PEG 400 (30:70)
PEG 3350: PEG 400 (50:50)
PEG 3350: PEG 400 (50:50)
PEG 4500: PEG 400 (15:85)
PEG 4500: PEG 400 (15:85)
PEG 4500: PEG 400 (20:80)
PEG 4500: PEG 400 (20:80)
PEG 4500: PEG 400 (30:70)
PEG 4500: PEG 400 (30:70)
PEG 4500: PEG 400 (50:50)
PEG 4500: PEG 400 (50:50)

Oil Phase
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil
Labrafil M1944 CS
Light mineral oil

Preparation of selected formulation using Twin screw processor
Hot melt extrusion method
Creams were prepared by co-rotating twin screw extruder (OMICRON 10, STEER Life) (Fig. 2).
6

For this method all the ingredients of aqueous phase and oil phase were weighed accurately and
the mixture was heated on a hot plate maintained at a temperature of 70±5ºC.

Figure 2. Omicron 10 [Mini] with Do/Di ratio 1.71 for manufacturing of the Cream formulation.
Based on the optimization of the screw with diameter ratio (Do/Di) 1.71 was selected for the
extrusion process. Processing parameters for twin screw processor are described in Table 2. Screw
speed was set to 200 RPM. Feeder speed was set to 30 rpm to feed the material at 1.8 g/min, and
0.595 - 1.19 mm particle size of PEG 2000 were used. Optimization of the peristaltic pump was
done to give proper feed at feeding zone and zone 2. For the optimization of the peristaltic pump
weight of material dispensed per minute vs RPM of the peristaltic pump was noted. A peristaltic
pump set to a flow rate of 45 RPM was used to dispense the aqueous phase at the feeding zone and
peristaltic pump set to a flow rate of pump 20 RPM was used to dispense the oil phase at the zone
2. After the optimization of both peristaltic pumps, the aqueous phase containing a 15:85 mixture
of PEG 2000 and PEG 400 was passed through the feeding zone. The peristaltic pump dispensing
the aqueous phase was set to an RPM of 45. The oil phase was introduced at zone 2 for proper
7

mixing with the aqueous phase. A peristaltic pump dispensing the oil phase was set to an RPM of
20. The RPM was adjusted according to the percentage of composition in aqueous phase (75%)
and oil phase (25%) as needed. At the end zone (collecting zone) creams which were prepared
were collected in a container and allowed to cool down to room temperature. The creams were
then refrigerated for further study.
Table 2. Processing parameters for the manufacturing of creams by Hot melt extrusion.
PARAMETERS
Equipment
Screw design
Barrel Diameter

DESCRIPTION
OMICRON 10 with Do/Di ratio 1.71, STEER Life
Co-rotating twin screw extruder
10 mm
Zone 1 - 70 ℃
Zone 2 - 40 ℃
200
0-3 Nm/Shaft

Barrel temperature
RPM
Torque

Characterization of Oil/PEG creams:
Differential Scanning Calorimetry (DSC) Analysis
DSC was performed to analyze the glass transition temperature and melting point of pure
ingredients and selected cream formulations. Thermograms were obtained using TA Instruments
Discovery Series DSC 25, New Castle, DE, USA. Analysis was performed over the temperature
range of 20°C to 200°C at 10°C increments. The nitrogen purge was set at 20°C/min. Samples
were weighed accurately (around 5 mg) in an aluminum pan, sealed with a hermetic lid. TRIOS
software was used as a means to analyze the solid-state characteristics and thermal stability of the
voriconazole, excipients and the formulations.
pH measurement
The pH of the creams was measured by using Mettler Toledo InLab®Micro pH probe (Electrolyte
3 mol/L KCl). The pH meter was calibrated using standard buffers with the known pH of 4.0, 7.0
8

and 10.0 respectively. The pH of each cream formulation was measured in triplicate (n=3). In
between every individual measurement, pH reading of the standard buffer pH 4.0 was taken
followed by next reading and a standard buffer of pH 10.0 respectively.
Solvent Activity (aW) measurements
The solvent activity of all cream formulations was measured by using AQUALAB water activity
meter series 3 and 3TE (Series 3E, USA) (Fig. 3). All measurements were performed at 32℃.

Figure 3. Water activity meter (Series 3E, USA)

Initially the instrument was calibrated using standards. A whole vial of solution was transferred
into a sample cup and was placed in the Aqualab’s sample drawer. Two readings were taken to get
the aw within ± 0.003 of the given value. Distilled water was then placed in the drawer and the
reading was noted, to ensure that it is within 1.000 ± 0.003. The instrument was found to be suitable
when the water activity for DI water was equal to 1.00. Once the calibration was done, activated
charcoal cup was kept in the drawer and the knob was turned on, in order to remove any moisture
present before running the samples. The values were noted in triplicate (n=3). In between each
reading activated charcoal was placed in the chamber to remove moisture. The samples were
analyzed in triplicate and the average of the values was reported.

9

Viscosity measurement
The viscosity of the prepared formulations was determined using a Brookfield viscometer (DVII+). The temperature maintained for the study was 21°C. The spindle (3.2 cm) RPM was set to
0.3. The instrument was allowed to stabilize for 15 minutes and readings were noted for each cream
formulation.

Figure 4. Brookfield viscometer (DV-II+)
LV-4 spindle was fit near the shipping cap of viscometer and the formulations were placed on the
guard leg, and the spindle was immersed into a glass vial. All the readings were taken in triplicate
(n=3).
Method of Analysis
1. High Performance Liquid Chromatography (HPLC).
2. Spectrophotometric analysis.
High Performance Liquid Chromatography (HPLC)
Analysis of voriconazole was done using a Waters HPLC system (Water 600 Controller, USA)
10

equipped with a 600-pump unit, a 717 plus auto sampler with an injection valve with a sample
loop of 50 µl, and a 2487 dual absorbance UV detector. Peak area integration was performed using
Breeze software. An isocratic HPLC method was developed for the quantification of voriconazole
[6,7]

. The method was validated for Sensitivity/Specificity, Linearity, Limit of detection (LOD),

Limit of quantitation (LOQ), measuring range, accuracy and precision. Processing parameters for
the HPLC method is described in table 3.
Table 3. Processing parameters for the HPLC method.
PARAMETERS

DESCRIPTION

Mobile phase

A mixture of Acetonitrile and Water
(50:50, v/v)

Column

A reversed-phase C18 column (25 cm × 4.6 mm i.d., particle
size 5 µm)

Detection wavelength

The UV detector wavelength was set at 256 nm for
voriconazole

Flow rate

1.0 mL min−1

Temperature

23 ± 1 ℃

Injection volume

25 µl

Retention time

3.8 minutes

Run time

9.00 minutes

Spectrophotometric Analysis
The analysis for voriconazole was carried out using a UV/VIS (Ultraviolet/Visible)
spectrophotometer (Model-1800, Shimadzu, Japan) at the absorbance maximum (λmax) of
voriconazole which was 256 nm using a quartz 96 well plate and against an appropriate blank. The
solvents used were the same as the release media. The dilution was necessary in order to get UV
absorbance readings below 1 [9].
11

Voriconazole Content Uniformity
To determine the content uniformity of the creams, 10 mg samples were withdrawn from three
different regions of the cream container [e.g. top, middle, bottom] and dissolved in 1 ml of DMSO
(Dimethyl Sulfoxide). The mixtures were vortexed using multi-vortexer V-32 Grant-bio for 15
minutes then subjected to sonication using FS60H (Fisher scientific) for 10 minutes. After
sonication, the mixtures were centrifuged using AccuSpin Micro 17 Centrifuge (Fisher scientific)
for 10 minutes and 100 µl of supernatant samples were collected and diluted up-to 1 ml with
DMSO. The concentration of the samples was analyzed using HPLC. All samples were analyzed
in triplicate. For analysis, a calibration curve of voriconazole ranging from 0.05 – 100 µg/ml was
used. Drug content uniformity was determined by using the following formula:

% 𝐷𝑟𝑢𝑔 Content =

𝐴𝑐𝑡𝑢𝑎𝑙 𝐷𝑟𝑢𝑔
𝑇ℎeoretical 𝐷𝑟𝑢𝑔

× 100

In-vitro Release Testing (IVRT)
IVRT is well established for characterizing and evaluating the performance of semi-solid dosage
forms

[33]

. IVRT can be a sensitive and discriminating method that is generally responsive to

physicochemical changes in semisolid drug products. The IVRT pivotal study comparing the
[drug] release rates of the products should be performed in a manner compatible with the general
procedures and statistical analysis method specified in the United States Pharmacopeia (USP)
General Chapter <1724>, Semisolid Drug Products – Performance Tests [8].
Drug Solubility Studies (Receptor Media Selection):
It is important to determine the solubility and stability of a drug in the receptor media. Drug
solubility studies are carried out to determine the ideal composition of the receptor media. To
12

determine the saturation solubilities of voriconazole, 1 mg of voriconazole was weighed and mixed
with 1 ml of various aqueous media with different compositions in 2 ml centrifuge tubes. The
aqueous media studied are described in Table 4. The tubes were continuously shaken for 24 hours
using a mechanical shaker. Samples were collected and subjected to centrifugation at 13,000 RPM
for 10-15 minutes. The resultant supernatants were collected and 10 times diluted with 80%
methanol (since voriconazole is poorly soluble in water). 200 µl sample were transferred into
HPLC vials for analysis. All the samples were analyzed in triplicate. A calibration curve of
voriconazole ranging from 0.05 – 100 µg/ml was used for all analysis.

Table 4. Various aqueous media with different concentrations for solubility studies.
Samples number
1
2
3
4
5
6
7
8
9
10

Media
0.2 % Brij S20
0.5 % Brij S20
1 % Brij S20
2 % Brij in 10 % PG
0.2 % Brij C20 (AP)
2 % PEG 400
1 % T80
1 % T20
10 % PG
PBS

Drug-stability in Receiver Medium
A standard stock solution ranging from 100 µg/ml-1 µg/ml was prepared. 100 µl of 100 µg/ml and
100 µl of 10 µg/ml was taken and dissolved in 10 ml of receiver medium (2 % Brij S-20 in 10 %
Propylene glycol) respectively. Both samples were vortexed for 5 minutes. From the mixture 500
µl was collected and another 500 µl of Acetonitrile (a common solvent used for the analysis of
voriconazole) was added and the samples were vortexed. Samples were refrigerated at – 20 ℃
13

(noted as initial concentration/ 0 hr. concentration). Remaining samples were also refrigerated for
48 hours. After 48 hours 500 µl was withdrawn and another 500 µl of Acetonitrile was added and
the samples were vortexed. The concentration of the samples was analyzed using HPLC. All the
samples were done in triplicate. For analysis calibration curve of voriconazole ranging from 0.1 –
100 µg/ml was used.
Membrane Inertness:
Membrane inertness is done to see if there is any binding of drug to membrane. The membrane
selected should offer free resistance to diffusion [8]. For the membrane inertness testing, three
different concentration (500 µg/ml (High concentration), 250 µg/ml (Intermediate concentration)
and 50 µg/ml (low concentration)) of standard stock solution of drug voriconazole was prepared.
Stock solution was centrifuged for 10 minutes. Supernatant was collected from each concentration
and added in the scintillation vials (All the samples were taken in triplicate, n=3). The selected
membrane (table 5) was cut into small circular shape and 1 ml of sample was withdrawn from the
centrifuge tube before soaking the membrane. The membrane was soaked in the scintillation tube
and kept aside for 24 hours. After 24 hours 200 µl of sample was withdrawn from each centrifuge
tubes and the before and after samples were analyzed using HPLC.
Table 5. Membrane for IVRT.

Membrane for IVRT
Membrane

Nylon

Pore size

0.22 µm

Diameter

0.47 mm

14

In-vitro drug release test
Vertical Franz diffusion cells with a volume of 5 ml (contact area: 0.64 cm2, Logan Instruments
Corp) were used to determine the in vitro drug release of the voriconazole from the formulations
(Fig. 5).

Creams

Figure 5. Franz diffusion cell.
Franz-cells were thoroughly washed with the buffer prior to starting release study. Donor cells and
rubber rings were washed with 50 % methanol and 50 % water and kept for sonication for 10
minutes. Dried donor cells and rubber rings were used for release study. Franz cells were connected
to the consoler and 5 ml of the receiver media was added. Stir bar was placed in each of the Franz
cells and turned on the consoler. Consoler was connected to the water jacket and temperature was
set to 32 ± 0.5 ℃. Nylon membranes were placed on top of the receptor chambers of the cells
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following the addition of the release media. Then the donor chambers were mounted on the
membranes and clamped tightly. 300 mg samples of the creams were loaded into the donor
chambers. The stirring speed of the Franz diffusion cells was set at 600 rpm. At pre-determined
time intervals (0, 1, 2, 3, 4, 5 and 6 hours), aliquots of 0.3 ml of the media were withdrawn from
the receptor chambers and replenished with fresh media. Processing parameter for IVRT is
described in table 6. Voriconazole was estimated spectrophotometrically at 256 nm. UV spectrum
of voriconazole was observed for voriconazole transported through the membrane at different time
period.
Table 6. IVRT parameters.
Illustrative IVRT parameters
Parameter

Description

Diffusion cell

5-station Franz diffusion cell

Weight of sample

300 mg of creams

Membrane

Nylon membrane, 0.47 mm diameter and 0.22 µm

Receptor media

2 % Brij S20 in 10 % propylene glycol

Temperature

32± 0.5 ℃

Sampling aliquot

300 µl

Sampling time

0, 1, 2, 3, 4, 5 and 6 hours

In-vitro Permeation Testing (IVPT)
Drug permeation through skin under in vitro conditions can be used to predict percutaneous
absorption in humans [10]. For the studies a fresh human cadaver skin (New York fire fighters skin
bank) stored in glycerin at a temperature of -20 ℃ was used. Prior to starting the experiment, the
skin was taken out and kept in phosphate buffer solution (PBS) in order to wash the glycerin from
the skin.
16

The in-vitro skin permeation study was performed using Franz diffusion cells with an effective
diffusion area of 0.64 cm2. A human cadaver skin was sandwiched between the donor and receiver
media with the subcutaneous (SC) side facing the donor compartment because of uniform diffusion
studies. The receiver compartment was filled with 5 ml of receptor media (2 % Brij S-20 in 10 %
propylene glycol) and temperature was maintained at 32 ± 0.5 °C. The dose for finite dose study
was 10 mg /cm2. In the finite dose regime, only a limited amount of the donor formulation is
applied to the skin surface. The application of a finite dose supposedly best resembles the in vivo
situation when applying e.g., a cream. The finite dose studies would be close to clinically relevant
dose and

it would reveal the way the formulation would behave and perform in the clinical

conditions. During the IVPT studies, at pre-determined time points (0, 4, 8, 12, 18, 24, 30 and 36
hours), aliquots of 0.2 ml of the media were withdrawn from the receptor chambers and replenished
with fresh media. The amount of voriconazole in these samples was quantified using HPLC. In
Finite dose study, the average flux was calculated and plotted to determine the maximum flux (J
max) and AUC0-t [11][12].
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CHAPTER III: RESULTS AND DISCUSSION
Screening of Excipients
Fourier Transform Infrared Spectroscopy (FT-IR)
The FT-IR spectra of the voriconazole, excipients and formulations were analysed to determine
the physical (H-bonding) or chemical interactions between API and Excipients. The voriconazole
powder exhibited absorption peaks at 3191 cm-1 corresponding to the stretching vibrations of OH.
The bands at 3000–2850, 1600–1400, and 1360–1250 cm-1 were assigned to the alkane CH, C =
C aromatic and aryl C-N stretches

[26][27][28]

as shown in the figure 10, 11, 12 and 13. The

formulations showed no major shifting of any functional peaks between the spectra of drug and
excipients alone. The characteristics peaks of drug in the formulations were diminished when
compared with pure drug peak at same wave number (3191 cm−1). The spectrum shows that there
are no drug-excipient interactions in the formulations.
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Figure 6. FT-IR of voriconazole, excipients and F9A.

Figure 7. FT-IR of voriconazole, excipients and F9B.
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Figure 8. FT-IR of voriconazole, excipients and F10A.

Figure 9. FT-IR of voriconazole, excipients and F10B.
Preparation and Optimization of Oil/PEG Creams
The preliminary screening of the formulations was done based on the stability and the
consistency of the formulations. In order to determine the stability, a three cycles of accelerated
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stability study was carried out using “freeze thaw stability” and later the formulations were
visually inspected for the phase separation and the consistency.
24 h at
Room
Temperature

24 h at
Room
Temperature

24 h at -20
°C

24 h at
Room
Temperature

24 h at 45
°C

Figure 10. Freeze thaw stability cycle.
Table 7. Compositions containing PEG 1450 and PEG 400, Subjected for Freeze thaw cycle.
Ingredients
PEG 1450
PEG 400
Propylene Glycol
API
Labrafil M 1944
CS*/Light mineral
oil**
Tefose 63

Percentage (%) of compositions
F3
F4
F5
F6
F7

F1

F2

F8

15
85
8
1

15
85
8
1

20
80
8
1

20
80
8
1

30
70
8
1

30
70
8
1

50
50
8
1

50
50
8
1

20*

20**

20*

20**

20*

20**

20*

20**

5

5

5

5

5

5

5

5

Table 8. Compositions containing PEG 2000 and PEG 400, Subjected for Freeze thaw cycle.
Ingredients
PEG 2000
PEG 400
Propylene Glycol
API
Labrafil M 1944
CS*/Light mineral
oil**
Tefose 63

F9

Percentage (%) of compositions
F10
F11
F12
F13
F14
F15

F16

15
85
8
1

15
85
8
1

20
80
8
1

20
80
8
1

30
70
8
1

30
70
8
1

50
50
8
1

50
50
8
1

20*

20**

20*

20**

20*

20**

20*

20**

5

5

5

5

5

5

5

5

Table 9. Compositions containing PEG 3350 and PEG 400, Subjected for Freeze thaw cycle.
Ingredients
PEG 3350
PEG 400
Propylene Glycol
API
Labrafil M 1944
CS*/Light mineral oil**

F17

Percentage (%) of compositions
F18
F19
F20
F21
F22
F23

F24

15
85
8
1

15
85
8
1

20
80
8
1

20
80
8
1

30
70
8
1

30
70
8
1

50
50
8
1

50
50
8
1

20*

20**

20*

20**

20*

20**

20*

20**
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Tefose 63

5

5

5

5

5

5

5

5

Table 10. Compositions containing PEG 4500 and PEG 400, Subjected for Freeze thaw cycle.
Ingredients
PEG 4500
PEG 400
Propylene Glycol
API
Labrafil M 1944
CS*/Light mineral
oil**
Tefose 63

Percentage (%) of compositions
F27
F28
F29
F30
F31

F25

F26

F32

15
85
8
1

15
85
8
1

20
80
8
1

20
80
8
1

30
70
8
1

30
70
8
1

50
50
8
1

50
50
8
1

20*

20**

20*

20**

20*

20**

20*

20**

5

5

5

5

5

5

5

5

* Formulation containing Labrafil M 1944 CS in oil phase.
** Formulation containing Light mineral oil in oil phase.
Composition – 75 % aqueous phase (Solid PEG, Liquid PEG, Propylene glycol and API) and 25
% oil phase (Labrafil M 1944 CS/ Light mineral oil and Tefose 63).
All the formulations (F1-F8) or the creams which had combinations of solid PEG (PEG 1450) and
Liquid PEG (PEG 400), showed phase separation after accelerated stability studies. Hence
formulations having combinations of PEG 1450 and PEG 400 were not selected for the further
studies. Formulations (F17-F24) or the creams which had combinations of solid PEG (PEG 3350)
and Liquid PEG (PEG 400) and the formulations (F24-F32) or the creams which had combinations
of solid PEG (PEG 4500) and Liquid PEG (PEG 400), had a very thick consistency. Hence the
formulations having combinations of PEG 3350, 4500 and PEG 400 were not selected for the
further studies either. Formulations (F13-F16) had higher percentage of solid PEG (PEG 2000) in
the compositions hence the consistency of the formulation was thick and was unable to transfer
the formulations into container because of the flakes like consistency. Hence formulations F13F16 were eliminated. Formulations (F9-F12) had an acceptable consistency and were considered
for further characterization. Microscopic images of the formulations (F11 and F12) showed a
distorted globule and the formulations (F9 and F10) showed a clear globule (figure.9 and 10).
Hence the formulations (F9 and F10) were selected for the further manufacturing and
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characterizations.

F11

F12

Figure 11. Microscopic images of formulation F11 and F12.

F9

F10

Figure 12. Microscopic images of formulation F9 and F10.
Preparation of Selected Formulations Using a Twin-Screw Processor
The base formulations F9 and F10 were selected for the manufacturing process after screening
studies.
Hot melt extrusion (HME): Selected four formulations (F9A, F9B (1 % API) and F10A, F10B
(3 % API)) were prepared in bulk using Hot melt extrusion process. Prepared formulations were
23

subjected to further characterizations.

Figure 13. Representation of the Hot melt extrusion setup.
Differential scanning calorimetry (DSC)
DSC was done to determine if voriconazole remains in the amorphous form in the formulation or
to know if it is soluble in the formulation (figure.14, 15, 16 and 17). The thermogram obtained
showed that the voriconazole had one endothermic peak at 127 ℃, which shows that voriconazole
exists only in one polymorphic form. Thermogram of the prepared creams, F10B showed complete
disappearance of the drug peak which suggests that either all the drug has been dissolved in the
base or the increase in temperature during DSC experimentation has solubilized the drug in the
base. Thermogram of the creams (F9A, F9B and F10A) showed very low intensity peaks, which
indicate that the crystalline peak of voriconazole either disappeared or shifted to lower
temperatures. This observation shows that the conversion of voriconazole from crystalline form to
amorphous form [30].
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Figure 14. DSC of pure components and F9A.

Figure 15. DSC of pure components and F9B.
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Figure 16. DSC of pure components and F10A.

Figure 17. DSC of pure components and F10B.
pH Measurements.
According to the pH/ partition theory, the unionized drug has more ability to permeate compared
to the ionized form of the drug. pH of the skin is considered to be around 5.5 and hence acceptable
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semisolid formulations should have a pH ranging from 5.5-7.0 to be compatible with the skin.
Voriconazole is a weak base (pKa 1.76) [37], the drug remains in the ionized state in the formulation
with pH above > 6. It was found that the pH of the topical products can change post application
on the skin due to homeostasis

[13] [14]

. The pH of all the prepared formulations did not differ

significantly.

Table 11. pH of the manufactured formulations.
Creams

pH

F9A

6.82±0.016

F9B

6.70±0.009

F10A

6.58±0.025

F10B

6.00±0.001

Solvent Activity (aW) Measurements
Solvent activity (aw) is simply defined as the ratio of the vapor pressure of pure water (100%
equilibrium relative humidity) over the vapor pressure of the sample. Solvent activity gives a clear
understanding about the formulations and its potential for microbial contamination. Solvent
activity of the prepared formulations was found to be low as described in table 12, however the
formulations did not have water in the compositions. Hence it can be concluded that the solvent
activity of the prepared formulations is accurate, since most of the creams are either Oil/Water and
Water/Oil creams which will have higher solvent activity. The formulations with low solvent
activity have significant influence on hydrodynamics of skin, and this was associated with
corresponding impacts on drug permeation and structural changes in stratum corneum layer
[15][16][17]

.
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Table 12. Solvent activity (aw) of the manufactured formulations.
Creams
F9A
F9B
F10A
F10B

Solvent Activity (aw)
0.288±0.016
0.251±0.019
0.193±0.028
0.173±0.025

Viscosity Measurements
It is essential to determine the viscosity of the formulations as it determines the free flow of the
formulation from the container ensuring the ease of administration. A viscosity range of (10 – 60)
104 cP is most common for topical formulations i.e., lotions, gels and creams [24][25]. Viscosity of
all the formulations were found well within the range.

Table 13. Viscosity measurement of the manufactured formulations.
Samples

Viscosity (cP)

F9A

(24.13±0.5033) X 104

F9B

(35.40±1.7088) X 104

F10A

(27.53±1.3317) X 104

F10B

(34.33±3.0022) X 104

Drug Content Uniformity
As mentioned earlier, uniform mixing of the API with cream base is one of the challenging tasks
in manufacturing of topical semi-solids. Uniformity of drug content indicates the efficiency of
mixing process and the relative standard deviation (RSD) of the drug content is a good indication
of the uniformity of the creams. In this study, we found that the drug content of all the prepared
creams were within the acceptable range of >90%, the limit set by the USP

[34]

. In addition, the

RSD of the drug concentration calculated based on samples taken from different regions of the
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creams was less than 3.5%, indicating adequate uniformity of the drug particles in the creams
[21][29]

.

Table 14. Drug content uniformity of the manufactured formulations.
Creams

Drug Content uniformity

F9A

100.42±0.77

F9B

105.51±2.57

F10A

101.36±0.45

F10B

103.20±1.78

In-vitro Release Testing (IVRT)
Drug Solubility Studies (Receptor media selection):
Prior to starting the IVRT, it is important to select the suitable receptor media which will allow the
drug to maintain sufficient sink condition. Screening of different aqueous media with varying
concentrations was done before selecting the suitable receptor media for the drug voriconazole
[18][19]

.

Table 15. Solubility studies results of various aqueous media with different concentrations.
Samples number
1
2
3
4
5
6
7
8
9
10

Media
0.2 % Brij S20
0.5 % Brij S20
1 % Brij S20
2 % Brij S20 in 10 % PG
0.2 % Brij C20 (AP)
2 % PEG 400
1 % T80
1 % T20
10 % PG
PBS

Solubility (µg/ml)
648.16
793.68
1033.73
1369.02
570.16
488.90
694.19
789.44
655.75
477.22

As shown in Table 15, voriconazole had a good solubility in 0.5 % BrijTM S-20, 1 % BrijTM S-20,
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2 % w/v BrijTM S-20 in 10 % propylene glycol and 1 % T20. But compared to other release medias,
voriconazole had the highest saturation solubility in 2 % w/v BrijTM S-20 in 10 % propylene glycol.
Hence 2 % w/v BrijTM S-20 in 10 % propylene glycol was selected as the release medium as it
completely solubilized voriconazole and had the maximum solubility for voriconazole with respect
to other release medias with different surfactants solutions.
Drug-Stability in Receiver Medium
A drug-degradation study is carried out to find if the drug is degraded in the receiver medium. The
degradation study was carried out at different concentrations (100 µg/ml and 10 µg/ml) of
voriconazole in the receiver medium. As shown in Table 16, voriconazole was not degraded in the
receiver medium.

Table 16. Drug stability in receiver medium.
Sample

Stability (%)

100 µg/ml

98.69

10 µg/ml

111.08

Membrane Inertness:
From the literature search it was found that nylon membrane, pore size 0.22 µm and diameter of
0.47 mm had previously been used in a release study of voriconazole [23] formulations. However,
it is important to know if there is any resistance to diffusion by the API caused by the membrane
and if release is proportional to the concentration of the drug in the formulation. A membrane
inertness study was done by using different concentrations of a standard voriconazole stock
solution. The samples were refrigerated at -20 ℃ for 24 hours. Before and after concentration of
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drug was analyzed using HPLC. For analysis calibration curve ranging from 0.1 µg/ml to 100
µg/ml was used. Nylon membrane, pore size 0.22 µm and diameter of 0.47 mm membrane was
selected because of its inertness to the API. There was negligible absorption of API on the
membrane before and after exposure to the drug solution. Hence it is concluded that the membrane
is not acting as a rate controlling barrier and the release is absolutely attributable to formulation
properties.

Table 17. Membrane inertness study results.
Samples

% Adsorbed to membrane

High concentration (500 µg/ml)

0.86

Medium concentration (250 µg/ml)

0.70

Low concentration (50 µg/ml)

0.10

In-vitro Drug Release Test
In-vitro release test was carried out using Franz diffusion cell (FDC), most commonly used in
topical semisolid formulations [33]. For the release study, 2 % w/v BrijTM S-20 in 10 % propylene
glycol (PG) was used as the receiver media and a nylon membrane (pore size 0.22 µm and diameter
of 0.47 mm) was used as the diffusion membrane. As shown in figure. 18. All of the four oil/PEG
cream formulations (F9A, F9B, F10A and F10B) prepared by the hot melt extrusion process
followed Higuchi’s release profile. Hence it can be concluded that hot melt extrusion can be used
as continuous process method of preparing an emulsion with the potential of enhancing the
solubility of API in the formulation and providing proper distribution of the API throughout the
composition. Comparing the four formulations, F10A (slope 3539.62) and F10B (slope 6854.44)
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had a higher rate of release profile compared to F9A (slope 1436.55) and F9B (slope 1966.08)

Cummulative drug release (µg/cm2)

(Figure 18).

Drug Release vs Sq. rt. of Time
15000

R² = 0.9942

12500
10000
R² = 0.9967
7500
5000

R² = 0.9919

2500
R² = 0.9961
0
0.50

1.00
F9A

1.50
Sq. rt. of time (h)
F9B

2.00

2.50

F10A

F10B

Figure 18. In-vitro drug release profile of the formulations.
In-vitro Permeation Testing (IVPT)
After in-vitro release test, formulations were subjected to permeation studies. However, for the
permeation studies formulations only the formulations which had 3 % voriconazole (F10A and
F10B) were selected. Since the water activity of these formulations was low, a low permeation
profile was expected. From the literature search it was found that, camphor-menthol (1:1) had
previously been used as a permeation enhancer for the formulations having voriconazole

[23]

.

Transcutol P at a low concentration was also explored as a permeation enhancer in the
formulations. Transcutol P, is an excellent solvent and powerful solubilizer and penetration
enhancer for topical formulations [35]. It is safe to use and has low irritancy inferred by numerous
toxicological studies and precedence of use in approved topical medicines

. As per the FDA’s

[35]

Inactive Ingredients Database for topical cream formulations, up to 15% w/v of Transcutol P has
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been used in FDA approved drug products [36]. In the current study only 7.5% w/v of Transcutol P
was used as permeation enhancer. For the permeation studies, formulations (F10A2 and F10B2)
containing 7.5% w/v camphor-menthol (1:1) were used as positive control, formulations without
permeation enhancer was used as negative control, and permeation enhancer activity of
formulations (F10A1 and F10B1) containing 7.5% w/v Transcutol P was tested. A finite dose
permeation study was carried out [22][23].
The finite dose permeation flux versus time profile followed a typical up and down curve in all the
formulations. The area under the curve (AUC) of the formulations (F10B1 and F10B2), had fivefold increment compared to the formulations without permeation enhancer; and formulations
(F10A1 and F10A2), had three-fold increment compared to the formulations without permeation
enhancer. The Jmax values of the formulations shown in Table16. Formulation with permeation
enhancer Transcutol P (F10B1) showed the highest flux/ Jmax. Formulation (F10B1) showed ninefold increment compared to the formulations without permeation enhancer and one-fold increment
compared to the formulation with permeation enhancer Camphor-menthol (1:1) (F10A2 and
F10B2).
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Table 18. Comparison of AUC (µg/cm2) and Jmax (µg/cm2/h).
Samples
Cream without
permeation enhancer
(Light mineral oil)
Cream without
permeation enhancer
(Labrafil M 1944 CS)

AUC (µg/cm2)

Flux (µg/cm2/h)

Tmax (h)

0.699±0.763

0.182±0.098

30±6.0000

0.535±0.304

0.115±0.075

22±3.4641

F10A1

1.315±1.038

0.355±0.264

8.67±8.0829

F10B1

2.550±0.789

0.909±0.302

4±0.0000

F10A2

1.562±1.005

0.554±0.393

6.67±4.6188

F10B2

2.552±2.025

0.873±0.751

6.67±4.6188

Cream without permeation
enhancer (Light mineral oil)

Flux (µg/cm2/h)

1.8

Cream without permeation
enhancer (Labrafil M1944
CS)
F10A1

1.6
1.4
1.2
1.0

F10B1

0.8
0.6
0.4
0.2
0.0
0

5

10

15

20

25

30

35

Time (h)
Figure 19. In-vitro drug permeation profile of the formulations.
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CHAPTER IV: CONCLUSION
Oil/PEG creams of voriconazole were successfully developed in order to overcome the
degradations problem of voriconazole in aqueous base formulations (i.e., Oil/Water or Water/Oil).
Stable voriconazole topical creams formulations was successfully developed and evaluated. Hotmelt extrusion was used in the manufacturing of voriconazole creams; suggesting the feasibility
of using hot melt extrusion as a continuous manufacturing tool for semi-solid formulations.
Further, it was found that transcutol P at a lower concentration can be used as permeation
enhancers over camphor-menthol (1:1). From the results it was clear that the permeation profile of
the formulations with permeation enhancer, transcutol P was much better than the permeation
profile of the formulations with permeation enhancer camphor-menthol (1:1).
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